BioNitrogen Holdings Corp. Appoints Graham Copley to Board of Directors
PR Newswire
MIAMI, Sept. 9, 2015
MIAMI, Sept. 9, 2015 /PRNewswire/ -- BioNitrogen Holdings Corp. (OTC PINK: BION), a Clean Tech company that owns breakthrough, disruptive technology to produce urea fertilizer from biomass, today announced the appointment of Graham Copley to its board of directors, effective immediately.
Graham Copley is a co-founder of Pentant LLC, a strategic advisory business based in Stamford, CT. Graham is a trained chemical engineer and has spent roughly half of his career in the chemical industry and half in investment research and investment banking.
"Graham brings a wealth of knowledge and experience in the Chemical and Financial Industries to BioNitrogen and will play a key role as we achieve crucial milestones to enable the construction of our first plant in Florida, and subsequent plants thereafter," said Carlos Contreras, chairman and chief executive officer of BioN. "His strategic approach and analytical insight in the chemicals space will be a tremendous asset to BioNitrogen. Pentant has been advising BioNitrogen since July and Graham's acceptance of this role indicates the level of commitment and confidence that Graham and his team have in our process and our future. We are pressing ahead diligently with the accounting work and engineering work that is required to get us to a final investment approval for the first plant," added Carlos.
Prior to founding Pentant, Graham Copley was Head of US Equities for Macquarie Securities Group, a Board director of Macquarie Securities USA for 3 years, and a member of the US management committee of Macquarie. Prior to Macquarie, Graham held the role of Global Head of Equity Research for HSBC. In addition to management roles in the equity business, he was a research analyst at Sanford C Bernstein & Co. LLC from 1996 to 2004, covering the chemical industry, where he was consistently ranked within the top three analysts in the sector.
"I am honored to have been selected to sit on BioNitrogen's board," said Graham. "What BioNitrogen is trying to do is not an easy undertaking, as there are very few examples of new technologies launching successfully in the broad Chemical sector over the last few decades. However, BioNitrogen has tried and tested technologies in most stages of the process and this makes things somewhat easier; but probably more important, the company has an offering that people want. While I am impressed by the number of US opportunities that appear to exist, in addition to the initial project, these may be overwhelmed at some stage by opportunities outside the US, where Urea prices are often significantly higher." Graham adds: "Right now, job one is to get the first plant approved, financed and under construction and both Pentant as an advisor and I as a director have no greater priority. The company is weeks away from the completion of audited financials, an important step for up-listing the stock to OTCQB, bringing us closer to breaking ground on the first plant."
AI
